Edition:
United Kingdom

Abiomed Inc (ABMD.OQ)

ABMD.OQ on NASDAQ Stock Exchange Global Select Market

313.22USD
25 Mar 2019
Change (% chg)

$-9.99 (-3.09%)
Prev Close
$323.21
Open
$321.30
Day's High
$322.04
Day's Low
$313.00
Volume
294,779
Avg. Vol
196,522
52-wk High
$458.50
52-wk Low
$274.02

Latest Key Developments (Source: Significant Developments)

Abiomed Reports 6 Pct Stake In Shockwave Medical As Of March 11
Thursday, 21 Mar 2019 

March 21 (Reuters) - Abiomed Inc ::ABIOMED REPORTS 6 PERCENT STAKE IN SHOCKWAVE MEDICAL, INC AS OF MARCH 11 - SEC FILING.  Full Article

Abiomed Creates FDA-Approved Checklist To Guide Treatment Decisions Regarding Impella RP Heart Pump
Monday, 4 Feb 2019 

Feb 4 (Reuters) - Abiomed Inc ::STATEMENT FROM ABIOMED ON RP NOTIFICATION.ABIOMED SAYS TO HELP PHYSICIANS DETERMINE IF IMPELLA RP IS RIGHT FOR THEIR PATIENTS, CO CREATED FDA-APPROVED CHECKLIST TO GUIDE TREATMENT DECISIONS - SEC FILING.  Full Article

FDA Is Evaluating Recent Study Suggesting Increased Mortality Rate In Patients Receiving Abiomed Impella RP System
Monday, 4 Feb 2019 

Feb 4 (Reuters) - U.S. Food and Drug Administration::FDA SAYS IS EVALUATING RECENT STUDY THAT SUGGESTS INCREASED RATE OF MORTALITY IN PATIENTS RECEIVING ABIOMED IMPELLA RP SYSTEM.FDA - BELIEVES WHEN DEVICE USED FOR APPROVED INDICATION IN APPROPRIATELY SELECTED PATIENTS, BENEFITS OF IMPELLA RP SYSTEM CONTINUE TO OUTWEIGH RISKS.FDA SAYS WILL WORK WITH ABIOMED TO ENSURE PRODUCT LABELING ADDRESSES POST-APPROVAL STUDY INTERIM RESULTS OF ABIOMED IMPELLA RP SYSTEM.  Full Article

Abiomed Q3 GAAP Earnings Per Share $0.97
Thursday, 31 Jan 2019 

Abiomed Inc ::ABIOMED ANNOUNCES Q3 FY 2019 RECORD REVENUE OF $201 MILLION, UP 30% OVER PRIOR YEAR.Q3 GAAP EARNINGS PER SHARE $0.97.Q3 REVENUE $201 MILLION VERSUS REFINITIV IBES ESTIMATE OF $196 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $0.94 -- REFINITIV IBES DATA.SEES FY 2019 REVENUE $780 MILLION.UPDATING FISCAL YEAR 2019 GUIDANCE FOR GAAP OPERATING MARGIN TO RANGE OF 29% TO 29.5% VERSUS PRIOR GUIDANCE OF 28% TO 30%.COMPANY IS UPDATING ITS FISCAL YEAR 2019 GUIDANCE FOR GAAP OPERATING MARGIN TO RANGE OF 29% TO 29.5%.  Full Article

Abiomed posts Q3 revenue at $201 mln
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Abiomed Inc ::ABIOMED ANNOUNCES PRELIMINARY Q3 FY 2019 REVENUE OF $201 MILLION, UP 30 PCT OVER PRIOR YEAR AND INCREASES FULL YEAR GUIDANCE.Q3 REVENUE $201 MILLION VERSUS REFINITIV IBES ESTIMATE OF $195.2 MILLION.SEES FY 2019 REVENUE ABOUT $780 MILLION.  Full Article

Abiomed Reports Q2 GAAP Earnings Per Share $1.09
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - Abiomed Inc ::ABIOMED ANNOUNCES Q2 FY 2019 RECORD REVENUE OF $182 MILLION, UP 37% OVER PRIOR YEAR.Q2 GAAP EARNINGS PER SHARE $1.09.Q2 REVENUE $181.8 MILLION VERSUS I/B/E/S VIEW $175.2 MILLION.Q2 EARNINGS PER SHARE VIEW $0.74 -- THOMSON REUTERS I/B/E/S.SEES FY 2019 REVENUE UP 29 TO 30 PERCENT.SEES FY 2019 REVENUE $765 MILLION TO $770 MILLION.MAINTAINING ITS FISCAL YEAR 2019 GUIDANCE FOR GAAP OPERATING MARGIN IN RANGE OF 28% TO 30%.  Full Article

Abiomed Announces Approval In India For The Impella Heart Pumps
Thursday, 26 Jul 2018 

July 26 (Reuters) - Abiomed Inc ::ABIOMED ANNOUNCES APPROVAL IN INDIA FOR THE IMPELLA 2.5®, IMPELLA CP® AND IMPELLA 5.0® HEART PUMPS AND FIRST INDIAN PATIENT TREATED.ABIOMED INC - IMPELLA 2.5, IMPELLA CP AND IMPELLA 5.0 HEART PUMPS RECEIVED CENTRAL DRUGS STANDARD CONTROL ORGANIZATION APPROVAL IN INDIA.  Full Article

Abiomed Announces European Approval For Impella 5.5(Tm)
Thursday, 5 Apr 2018 

April 5 (Reuters) - Abiomed Inc ::ABIOMED ANNOUNCES EUROPEAN APPROVAL (CE MARKING) FOR IMPELLA 5.5(TM) AND FIRST PATIENT TREATED AT UNIVERSITY HEART CENTER HAMBURG.  Full Article

Abiomed Says Entered Settlement With U.S. DoJ Resolving Claims Related To Employee Meals
Thursday, 8 Mar 2018 

March 8 (Reuters) - Abiomed Inc ::ABIOMED - ON MARCH 6, ENTERED SETTLEMENT WITH U.S. DOJ RESOLVING CLAIMS ON CO'S REIMBURSEMENT OF EMPLOYEE EXPENSES FOR MEALS WITH HEALTHCARE PROVIDERS.  Full Article

Abiomed Reports Preliminary Q3 FY 2018 Revenue Of $154 Mln, Up 34 Pct Over Prior Year
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Abiomed Inc ::ABIOMED ANNOUNCES PRELIMINARY Q3 FY 2018 REVENUE OF $154 MILLION, UP 34% OVER PRIOR YEAR.Q3 REVENUE $154 MILLION VERSUS I/B/E/S VIEW $147.9 MILLION.  Full Article

Photo

Two years in, Trump holds stock market bragging rights

SAN FRANCISCO U.S. President Donald Trump has taken credit for the stock market's gains during his nearly two years in the White House, and those claims are reasonable given the impact of tax cuts and pro-business policies on investor sentiment. | Video